Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.9697
-0.0403 (-3.99%)
Apr 29, 2026, 1:16 PM EDT - Market open
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
2.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| Ensysce Biosciences | 5.07M |
| 60 Degrees Pharmaceuticals | 1.41M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Azitra | 7.50K |
VBIO News
- 1 day ago - VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME - PRNewsWire
- 5 days ago - Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model - PRNewsWire
- 14 days ago - Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th - PRNewsWire
- 27 days ago - Valion Bio Transcript: Emerging Growth Conference 91 - Transcripts
- 4 weeks ago - Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod - Accesswire
- 4 weeks ago - Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference - Accesswire
- 4 weeks ago - Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome - Accesswire
- 4 weeks ago - Valion Bio Earnings Call Transcript: Q4 2025 - Transcripts